Deep Vein Thrombosis: Global Therapeutic Landscape Pipeline Review, H1 2018

Deep Vein Thrombosis

PUNE, MAHARASHTRA, INDIA, February 19, 2018 / --
Deep Vein Thrombosis


Deep Vein Thrombosis is re-narrowing of a blood vessel which leads to restricted blood flow. Symptoms include shortness of breath, difficulty walking and chest pain. Risk factors include increasing age, gender, family history or race and diabetes. Treatment includes surgery and thrombolytic therapy.

Click here for sample report @

Top Companies mentioned

Dong-A Socio Holdings Co Ltd

Hoffmann-La Roche Ltd
Generex Biotechnology Corp

GlycoMimetics Inc

Laboratorios Farmaceuticos Rovi SA

Deep Vein Thrombosis Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Deep Vein Thrombosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Deep Vein Thrombosis - Competitive Analysis

Key players are making innovative developments in Deep Vein Thrombosis industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector


The pipeline guide provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis.

The pipeline guide reviews pipeline therapeutics for Deep Vein Thrombosis by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Deep Vein Thrombosis therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Deep Vein Thrombosis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Deep Vein Thrombosis.


For Detailed Reading Please visit @

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.